Pacira BioSciences, Inc.
corporate_fare Company Profile
Pacira BioSciences, Inc. (NASDAQ:PCRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 52 items for PCRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PCRX spans 8-K, SC 14D9/A, 10-Q, SC 14D9.
Recent high-impact activity:
- Viatris Closes $36.50-a-Share Takeover of Pacira
- Ninth Circuit Reverses Pacira's EXPAREL Royalty Win, Reviving RDF Royalty on 200-Liter Process
- Pacira Discloses Two Merger Suits and 15 Demand Letters Over 14D-9 Disclosures
- Pacira Q3 Net Income Jumps to $28.5M as Viatris Tender Offer Runs
- Pacira Cancels Q3 Earnings Release and Withdraws 2026 Guidance Pending Viatris Deal
Financial Snapshot
Short Interest & Short Volume
3.91 days to coverFINRA reported short interest of 3,348,320 shares in PCRX as of the October 30, 2026 settlement, a 21.4% decrease from the prior period — about 3.9 days to cover at its recent average daily volume. On November 16, 2026, 68.9% of PCRX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.